Regeneron Pharmaceuticals, Inc. (REGN) Management Presents on Investor Event ASH 2020 Conference Call TranscriptSeeking Alpha • 12/08/20
Regeneron's BCMAxCD3 Bispecific Antibody (REGN5458) Shows Deep and Durable Responses in Patients with Heavily-pretreated Multiple Myeloma in Phase 1PRNewsWire • 12/05/20
Regeneron (REGN) Down 16.4% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 12/05/20
Scott+Scott Attorneys at Law LLP Continues Investigation of Regeneron Pharmaceuticals, Inc.'s Directors and Officers for Breach of Fiduciary Duty – REGNBusiness Wire • 12/02/20
Regeneron Pharmaceuticals' (REGN) Management Presents at Piper Sandler 32nd Annual Virtual Healthcare Conference (Transcript)Seeking Alpha • 12/02/20
Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Evercore ISI 3rd Annual HealthCONx Conference (Transcript)Seeking Alpha • 12/01/20
Regeneron Announces Investor Webcast at American Society of Hematology 2020 Annual MeetingPRNewsWire • 11/30/20
Regeneron will provide 300,000 doses of Covid treatment for U.S. by early January, CEO Schleifer saysCNBC • 11/23/20
Regeneron's Coronavirus Treatment Becomes First Antibody Cocktail to Earn Emergency Use Authorization from FDAThe Motley Fool • 11/22/20
Regeneron's REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use AuthorizationPRNewsWire • 11/22/20